Concerns from Eating Disorder Experts
Eating disorder organizations are voicing alarms about the swift introduction of GLP-1 weight-loss therapies via telehealth, coupled with what they see as forceful social media promotions from various providers.
In a specific scenario, a provider alluded to 'irksome Aussie regulations' blocking fuller details on the drug for prospective clients.
The Australia and New Zealand Academy for Eating Disorders worries that these promotional methods might draw in individuals who don't actually require the treatment.
Ms Gooding from Brisbane noted that eating disorder support groups are seeing instances of people abusing the drugs or obtaining them inappropriately.
Juniper's Black Friday Sale
Global firm Juniper stands out among their worries, having conducted a recent Black Friday promotion.
Juniper belongs to EUC Management, also known as Eucalyptus, with bases in Australia, the UK, Germany, and Japan.
Its earnings surged over twofold to $248 million in the prior fiscal year, as per regulatory filings for 2025.
Despite that, it incurred a $25 million deficit last year, with its primary expense being advertising at $86.1 million, nearly tripling from the previous period.
A sister company under the same group, Pilot, offers comparable medical weight-loss options aimed at men, whereas Juniper focuses on females.
Doctors from both entities can issue prescriptions for drugs like Wegovy (semaglutide) and Mounjaro (tirzepatide), akin to Ozempic.
Black Friday Deals and Australian Rules
Juniper faced inquiries about a previous Black Friday offer and its tie to prescription drugs, following ads with voucher codes and promotional emails.
Eucalyptus's clinical head, Dr Matt Vickers, stated in a response that promotions pertained only to the price of accessing their healthcare service, excluding medication costs.
Brisbane student Evangeline Gardiner reported feeling overwhelmed by ads.
'It feels as though their primary interest is in profits, not my personal well-being or health,' she commented.
The 30-year-old, with a history of irregular eating patterns, found the ads especially distressing.
'It's unsettling to see a Black Friday discount for such a product.'
Observations from Juniper's Facebook revealed a reply advising a user to private message for extra details due to 'irksome Aussie laws'.
Australia enforces strict bans on public ads for prescription drugs.
Advertising limits don't cover health service promotions that avoid mentioning specific treatments and only describe consultation types.
Juniper clarified that the social media remark didn't align with the company's stance on rules.
The firm regularly engages on social platforms, urging private chats for more on weight-loss options.
'We prioritize adherence and back Australia's framework for telehealth and drugs,' Dr Vickers remarked.
'We apologize for the statement and recognize it might have raised issues.'
'The post was deleted, and we've examined our procedures for enhancements.'
Dr Vickers noted the Black Friday deal 'had no impact on a doctor's prescribing choice; suitability comes from a thorough clinical review'.
'We understand promotions in this area need careful handling, so our clinical protections and vetting stay constant for each client.'
Logos from groups like the Royal Australian College of General Practitioners (RACGP) and the Australian College of Nurse Practitioners appeared on Juniper's site.
After inquiries, those were taken down.
A RACGP representative stated 'weight-loss drugs must be given only under defined medical guidelines with continuous oversight'.
